Saturday 17 October 2026
Export CRVO’s income statement to Excel — free account
CervoMed Inc.
CRVO Healthcare Biotechnology
CervoMed Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, down 58.9% from fiscal 2024. In the quarter to June 2026, revenue fell 99.6%, EPS grew 8.57% and free cash flow fell 6.20%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.24
0.01
−0.44%
Follow CRVO
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | — | — | — | 2 |
P/E ratio |
— | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | — | — | — | — | (3.93) | 0.55 | 0.28 |
P/S ratio |
— | — | — | — | — | — | — | 2.98 | 1.94 | 17.83 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | — | — | (15.23) | 8.38 | (12.90) |
P/FCF ratio |
— | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | — | — | — | — | — | — | (8.39) | (2.35) | (10.86) |
Beneish M-Score |
— | — | — | — | — | — | — | — | (1.18) | (4.94) |
P/B ratio |
— | — | — | — | — | — | — | 2.89 | 0.48 | 3.92 |
Price to Tangible BV |
— | — | — | — | — | — | — | 0.00 | 0.62 | 7.45 |
EV/Sales |
— | — | — | — | — | — | — | 3.70 | (0.73) | 15.86 |
EV/EBITDA |
— | — | — | — | — | — | — | 0.00 | 0.39 | 0.00 |
EV/Operating CF |
— | — | — | — | — | — | — | (3.55) | 0.43 | (2.71) |
EV/FCF |
— | — | — | — | — | — | — | (3.35) | 0.42 | (2.66) |
Quick Ratio |
0.35 | 3.31 | 9.94 | 8.24 | 7.60 | 12.75 | 5.52 | 3.35 | 10.61 | 4.57 |
Current Ratio |
0.36 | 3.59 | 11.09 | 8.51 | 7.71 | 12.92 | 5.61 | 3.84 | 11.11 | 4.91 |
Net Debt/EBITDA |
(0.05) | 0.74 | 0.67 | 1.23 | 1.16 | 1.52 | (2.39) | 1.00 | 2.14 | 0.74 |
Debt/Assets |
13.90% | 2.10% | 0.00% | 0.56% | 0.13% | 0.00% | 298.58% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.26 | 0.03 | 0.00 | 0.01 | 0.00 | 0.00 | (1.38) | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 0.37 | 0.12 |
Operating CF/Net income |
0.60 | 4.71 | 0.40 | 0.84 | 0.84 | 0.60 | 0.44 | 3.43 | 1.01 | 0.87 |
Capex/Depreciation |
(0.09) | (6.59) | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | — | — | — |
Interest Coverage |
(618.58) | (236.43) | 125.06 | (135.43) | (139.76) | (179.47) | (5,792.50) | — | — | — |
| (394.54%) | (17.21%) | (144.53%) | (66.02%) | (71.80%) | (80.69%) | (713.60%) | 16.77% | (69.95%) | (93.92%) | |
| (182.55%) | (12.00%) | (120.07%) | (55.77%) | (62.25%) | (73.50%) | (27.64%) | (30.74%) | (61.41%) | (81.77%) | |
ROIC |
(114.12%) | (55.05%) | (155.49%) | (118.50%) | (157.62%) | 0.00% | 0.00% | 0.00% | (4,064.19%) | 0.00% |
Return on Tangible Assets |
654.71% | (35.19%) | (314.68%) | (89.52%) | (97.85%) | (69.05%) | (169.87%) | (29.47%) | (41.56%) | (147.98%) |
Average Days of Receivables |
— | — | — | — | — | — | — | 46.76 | 84.49 | 38.90 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 118.11% | 193.04% | 544.54% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 91.24% | 94.13% | 261.68% |
Intangible Assets out of Total Assets |
0.89 | 0.60 | 0.47 | 0.36 | 0.31 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 5.70% | 14.44% | 36.16% |
Graham Net Nets |
— | — | — | — | — | — | — | 0.35 | 2.08 | 0.26 |
Graham Number |
— | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | — | — | — | (10.20%) | (86.75%) | (37.72%) |
Free Cash Flow Yield |
— | — | — | — | — | — | — | (37.05%) | (89.82%) | (33.44%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.69 | 1.21 | 0.44 |
Operating CF per Share |
(1,183.33) | (1,121.13) | (249.37) | (110.27) | (18.88) | (11.17) | (4.97) | (2.80) | (2.05) | (2.59) |
Capex per Share |
(0.25) | (40.71) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(1,183.58) | (1,161.84) | (249.37) | (110.27) | (18.88) | (11.17) | (4.97) | (2.80) | (2.05) | (2.59) |
Cash per Share |
170.65 | 808.77 | 184.98 | 158.58 | 25.79 | 28.74 | 7.90 | 2.93 | 4.82 | 2.31 |
Shareholders Equity per Share |
1,009.31 | 1,929.99 | 361.38 | 225.22 | 34.57 | 26.89 | (17.37) | 2.77 | 4.86 | 2.02 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1,009.31 | 1,929.99 | 361.38 | 225.22 | 34.57 | 26.89 | (17.37) | 2.77 | 4.86 | 2.02 |
Free Cash Flow |
(10.77) | (12.78) | (10.77) | (9.86) | (13.55) | (14.50) | (2.57) | (7.45) | (16.53) | (23.45) |
Working Capital |
(2.83) | 6.98 | 8.11 | 12.93 | 16.34 | 34.90 | 3.42 | 7.37 | 39.20 | 18.22 |
Capital Expenditures |
0.00 | (0.45) | — | — | — | 0.00 | — | — | — | — |
Net Current Asset Value |
(6.70) | 4.75 | 6.32 | 10.67 | 15.86 | 34.90 | (9.00) | 7.37 | 39.20 | 18.22 |
EV/EBIT |
— | — | — | — | — | — | — | 0.00 | 0.39 | 0.00 |
Capex to Sales |
0.00 | 0.00 | — | — | — | 0.00 | — | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.32 | 0.15 | 20.10 | 0.39 | 0.69 | 0.00 | 0.00 | — | — | — |
Cash ROIC |
(81.80%) | (41.66%) | (45.64%) | (28.62%) | (31.25%) | (20.07%) | (34.26%) | (49.11%) | (21.16%) | (59.99%) |
Accounts Receivable Turnover |
— | — | — | — | — | — | — | 14.47 | 6.14 | 2.99 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Average Receivables |
— | — | — | — | — | — | — | 0.49 | 1.58 | 1.34 |
Average Payables |
1.05 | 1.10 | 0.36 | 0.73 | 0.90 | 0.75 | 0.52 | 0.38 | 1.09 | 1.48 |
Average Assets |
9.88 | 21.82 | 22.17 | 21.16 | 25.92 | 32.78 | 21.00 | 7.07 | 26.53 | 32.98 |
Average Common Equity |
4.57 | 15.21 | 18.42 | 17.87 | 22.47 | 29.86 | 0.81 | (12.95) | 23.29 | 28.71 |
Columns are period end dates